Puma Biotechnology Research Coverage Started at Stifel Nicolaus (PBYI)

Share on StockTwits

Stifel Nicolaus assumed coverage on shares of Puma Biotechnology (NASDAQ:PBYI) in a report released on Tuesday. The firm issued a hold rating on the stock.

Shares of Puma Biotechnology (NASDAQ:PBYI) opened at 249.91 on Tuesday. Puma Biotechnology has a 1-year low of $33.70 and a 1-year high of $263.34. The stock’s 50-day moving average is $166.2 and its 200-day moving average is $108.3. The company’s market cap is $7.527 billion.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings data on Monday, August 11th. The company reported ($1.05) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.66) by $0.39. Analysts expect that Puma Biotechnology will post $-3.93 EPS for the current fiscal year.

Several other analysts have also recently commented on the stock. Analysts at Citigroup Inc. raised their price target on shares of Puma Biotechnology from $99.00 to $292.00 in a research note on Wednesday, July 23rd. They now have a buy rating on the stock. Separately, analysts at Leerink Swann raised their price target on shares of Puma Biotechnology from $144.00 to $300.00 in a research note on Wednesday, July 23rd. They now have an outperform rating on the stock.

Puma Biotechnology, Inc is a development-stage biopharmaceutical company that acquires and develops products for the treatment of various forms of cancer.

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.

Latest News

Washington Real Estate Investment Trust Given Consensus Rating of “Hold” by Brokerages
Washington Real Estate Investment Trust Given Consensus Rating of “Hold” by Brokerages
Qunar Cayman Islands Receives Consensus Rating of “Buy” from Analysts
Qunar Cayman Islands Receives Consensus Rating of “Buy” from Analysts
Neurocrine Biosciences Given Average Rating of “Buy” by Brokerages
Neurocrine Biosciences Given Average Rating of “Buy” by Brokerages
Astoria Financial Corp Given Consensus Recommendation of “Hold” by Analysts
Astoria Financial Corp Given Consensus Recommendation of “Hold” by Analysts
KBR Receives Average Recommendation of “Buy” from Analysts
KBR Receives Average Recommendation of “Buy” from Analysts
Vanguard Natural Resources Given Consensus Recommendation of “Hold” by Analysts
Vanguard Natural Resources Given Consensus Recommendation of “Hold” by Analysts


Leave a Reply

 
Advertisement
Advertisement
© 2006-2014 Mideast Time.